Percutaneous Endovascular Arch Repair Trial (PEART) Study

Inclusion Criteria: 1. Patients aged 18 to 80 years old 2. Patients diagnosed with aortic arch disease requiring intervention, including non-A-non-B aortic dissection, or residual dissection after type A ascending aortic repair; aortic arch aneurysms. 3. Patients with suitable vascular conditions, including: 1. Ascending aorta (including surgical graft) length greater than 30 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery). 2. Proximal anchoring zone diameter ≥ 24 mm and ≤ 47 mm; 3. Proximal anchoring zone length ≥ 20 mm; 4. Innominate artery, left common carotid artery and left subclavian artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm； 5. Suitable arterial access for endovascular interventional treatment; 4. Patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol. 5. Evaluated by at least two investigators that the subjects are high-risk patients with more complications, poor general condition, high risk of deep hypothermic circulatory arrest, and not suitable for total arch replacement and other surgical procedures. Exclusion Criteria: 1. Previously received open surgery or endovascular intervention for descending aorta or abdominal aorta; 2. Infectious aortic disease, takayasu arteritis, Marfan syndrome (or other connective tissue diseases ); 3. Patients that have experienced systemic infection within past three months; 4. Neck surgery was performed within past three months; 5. Patients with severe stenosis, calcification, thrombosis or tortuosity in the brachiocephalic trunk, left common carotid artery or left subclavian artery; 6. Patients with intestinal necrosis and lower limb ischemic necrosis; 7. Paraplegic patients; 8. Heart transplant patients; 9. Patients that have suffered MI or stroke within past three months; 10. Patients with Class IV heart function (NYHA classification) or LVEF\<30% 11. Active peptic ulcers or upper gastrointestinal bleeding occurring within the past three months; 12. Hematological abnormality, defined as follows: Leukopenia (WBC \< 3 × 109/L), anemia (Hb \< 90 g/L); coagulation dysfunction, thrombocytopenia (PLT count\< 50 × 109/L); 13. Patients with renal insufficiency， serum creatinine \> 150 umol/L (or 3.0 mg/dl) and / or end-stage renal disease requiring dialysis, shall be determined by the investigator after a comprehensive analysis; 14. Patients with severe liver dysfunction: ALT or AST exceeding 3 times the upper limit of norma, serum total bilirubin (STB) exceeds 2 times the upper limit of normal; 15. Patients who are allergic to contrast agents; 16. Patients that are pregnant or breastfeeding; 17. Patients with severe comorbidities who cannot tolerate anesthesia and surgery; 18. Patients with a life expectancy of less than 12 months; 19. Patients currently participating in other drug or device study; 20. The investigator assessed that the patient was ineligible for the study for other diseases or abnormalities.